Pediatric Clinic, Università degli Studi di Perugia, Perugia, Italy.
Pediatric Highly Intensive Care Unit, Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Vaccine. 2018 Aug 28;36(36):5442-5448. doi: 10.1016/j.vaccine.2017.07.099. Epub 2017 Aug 4.
The clinical relevance of herpes zoster (HZ) and its increased incidence in recent years has prompted a search for more effective measures of prevention and therapy. A number of vaccines has been developed. For two of them, the live attenuated HZ vaccine (LAHZV) and the adjuvanted recombinant subunit HZ vaccine (SUHZV), data regarding immunogenicity, efficacy, safety and reactogenicity have been collected. This information allows us to draw some conclusions about what can be expected from their use and what is still required to definitively solve the problem of HZ prevention. The currently licensed vaccine LAHZV is only partially satisfactory in terms of efficacy, but it is safe and exhibits acceptable reactogenicity. Because LAHZV is also highly cost effective, it should be used as widely as possible until new, more effective preparations are developed. In this regard, preliminary data regarding SUHZV are very promising, although more studies are needed before it can be licensed for routine use. Other vaccines, such as the inactivated VZV vaccine, are in development. It seems likely that in the near future, more effective HZ prevention for older adults can be achieved.
带状疱疹（HZ）的临床相关性及其近年来发病率的增加促使人们寻找更有效的预防和治疗措施。已经开发出许多疫苗。对于其中两种疫苗，即减毒活带状疱疹疫苗（LAHZV）和佐剂重组亚单位带状疱疹疫苗（SUHZV），已经收集了关于其免疫原性、疗效、安全性和反应原性的数据。这些信息使我们能够对其使用效果做出一些结论，以及仍需要哪些措施来彻底解决 HZ 的预防问题。目前获得许可的 LAHZV 疫苗在疗效方面仅部分令人满意，但它是安全的，且具有可接受的反应原性。由于 LAHZV 也具有很高的成本效益，因此应尽可能广泛地使用，直到开发出更有效、更新的制剂。在这方面，关于 SUHZV 的初步数据非常有希望，尽管在获得常规使用许可之前还需要更多的研究。其他疫苗，如灭活 VZV 疫苗，也正在开发中。在不久的将来，老年人更有效的 HZ 预防措施似乎是可以实现的。
